Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis
- 16 October 2024
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 475-484
Abstract
On October 6, 2023, the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation and dosage of Cosentyx® (secukinumab), for the treatment of adult patients with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active non‐radiographic axial spondyloarthritis (nr‐axSpA) with objective signs of inflammation. Clinical pharmacokinetics (PK), efficacy, and short‐term placebo‐controlled safety data were available from clinical studies (NCT04156620 and NCT04209205) with the to‐be‐marketed IV formulation using a maintenance dosage 3 mg/kg every 4 weeks (q4w), which was different from the dose approved (1.75 mg/kg q4w). The IV dosage of 3 mg/kg utilized in these two trials resulted in exposures (Cmax,ss) significantly higher than those for the approved subcutaneous (SC) regimens. Further, there is limited long‐term safety information available for this 3 mg/kg q4w IV dose. To address this important limitation, a model‐informed drug development (MIDD) approach was employed to leverage available clinical PK, efficacy, and safety data from the secukinumab development program to identify a maintenance IV dosing regimen, 1.75 mg/kg IV q4w, that better approximated the relevant SC secukinumab exposures for which efficacy and safety have been established. The MIDD analyses were used to support approval of this IV dosing regimen not directly studied in the indications sought for licensure, PsA, AS, and nr‐AxSpA.Keywords
This publication has 10 references indexed in Scilit:
- Psoriatic arthritis from a mechanistic perspectiveNature Reviews Rheumatology, 2022
- Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safetyPharmacology & Therapeutics, 2022
- Secukinumab effective for nr-axSpANature Reviews Rheumatology, 2020
- Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and SimulationCPT: Pharmacometrics & Systems Pharmacology, 2019
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisArthritis Care & Research, 2019
- A Novel Pharmacokinetic Bridging Strategy to Support a Change in the Route of Administration for BiologicsJournal of Pharmaceutical Sciences, 2019
- Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance dataArthritis Research & Therapy, 2019
- Psoriatic ArthritisNew England Journal of Medicine, 2017
- Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe PsoriasisThe Journal of Clinical Pharmacology, 2017
- Ankylosing Spondylitis and Axial SpondyloarthritisNew England Journal of Medicine, 2016